Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes

Circulation: Cardiovascular Genetics

Volumn 6, Issue 2, 2013, Pages 184-192

  Lewis, Joshua P ^a   Ryan, Kathleen ^a   O'Connell, Jeffrey R ^a   Horenstein, Richard B ^a   Damcott, Coleen M ^a   Gibson, Quince ^a   Pollin, Toni I ^a   Mitchell, Braxton D ^a   Beitelshees, Amber L ^a   Pakzy, Ruth ^a   Tanner, Keith ^a   Parsa, Afshin ^a   Tantry, Udaya S ^b   Bliden, Kevin P ^b   Post, Wendy S ^c   Faraday, Nauder ^c   Herzog, William ^b,c   Gong, Yan ^d   Pepine, Carl J ^e   Johnson, Julie A ^d   Gurbel, Paul A ^b   Shuldiner, Alan R ^a,f   more..

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^f BALTIMORE VA MEDICAL CENTER   (United States)

Author keywords

CYP2C19; PEAR1; Percutaneous coronary intervention; Pharmacogenomics; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHROMOSOME 1Q; CLINICAL TRIAL; EX VIVO STUDY; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEART INFARCTION; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ENDOTHELIAL AGGREGATION RECEPTOR 1 GENE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION;

ADULT; AGED; ALLELES; CHROMOSOMES, HUMAN, PAIR 1; COHORT STUDIES; CORONARY ARTERY DISEASE; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CELL SURFACE; TICLOPIDINE;

EID: 84878084293     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.111.964627     Document Type: Article

References (27)

1. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart indicate Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, writing on behalf of the 2005 writing committee. Circulation. 2008;117:261-295.
2. Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv. 2009;74:E25-E68.
3. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, Jacobs AK, Morrison DA, Williams DO, et al ACC/AHA/SCAI. 2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J Am Coll Cardiol. 2008;51:172-209.
4. Feher G, Feher A, Pusch G, Koltai K, Tibold A, Gasztonyi B, et al. Clinical importance of aspirin and clopidogrel resistance. World J Cardiol. 2010;2:171-186.
5. Tantry US, Mahla E, Gurbel PA. Aspirin resistance. Prog Cardiovasc Dis. 2009;52:141-152.
6. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
7. Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, et al Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309-1311.
8. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
9. Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980-1987.
10. Zuern CS, Schwab M, Gawaz M, Geisler T. Platelet pharmacogenomics. J Thromb Haemost. 2010;8:1147-1158.
11. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
12. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
13. Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108:2244-2247.
14. Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, et al. Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008;101:1088-1093.
15. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-1830.
16. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19&z.ast;2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56:134-143.
17. Feher G, Feher A, Pusch G, Lupkovics G, Szapary L, Papp E. The genetics of antiplatelet drug resistance. Clin Genet. 2009;75:1-18.
18. Agúndez JA, Martínez C, Pérez-Sala D, Carballo M, Torres MJ, García- Martín E. Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009;10:998-1008.
19. Herrera-Galeano JE, Becker DM, Wilson AF, Yanek LR, Bray P, Vaidya D, et al. A novel variant in the platelet endothelial aggregation receptor- 1 gene is associated with increased platelet aggregability. Arterioscler Thromb Vasc Biol. 2008;28:1484-1490.
20. Beitelshees AL, Gong Y, Wang D, Schork NJ, Cooper-Dehoff RM, Langaee TY, et al INVEST Investigators. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007;17:719-729.
21. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-2816.
22. Agarwala R, Biesecker LG, Hopkins KA, Francomano CA, Schaffer AA. Software for constructing and verifying pedigrees within large genealogies and an application to the Old Order Amish of Lancaster County. Genome Res. 1998;8:211-221.
23. Agarwala R, Biesecker LG, Tomlin JF, Schäffer AA. Towards a complete North American Anabaptist genealogy: a systematic approach to merging partially overlapping genealogy resources. Am J Med Genet. 1999;86:156-161.
24. Nanda N, Bao M, Lin H, Clauser K, Komuves L, Quertermous T, et al. Platelet endothelial aggregation receptor 1 (PEAR1), a novel epidermal growth factor repeat-containing transmembrane receptor, participates in platelet contact-induced activation. J Biol Chem. 2005;280:24680-24689.
25. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010;42:608-613.
26. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera-Galeano JE, Suktitipat B, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood. 2011;118:3367-3375.
27. Kauskot A, Di Michele M, Loyen S, Freson K, Verhamme P, Hoylaerts MF. A novel mechanism of sustained platelet alphaiibbeta3 activation via pear1. Blood. 2012;119:4056-4065.